Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination.

Nature neuroscience | 2013

The lack of therapies for progressive multiple sclerosis highlights the need to understand the regenerative process of remyelination that can follow CNS demyelination. This involves an innate immune response consisting of microglia and macrophages, which can be polarized to distinct functional phenotypes: pro-inflammatory (M1) and anti-inflammatory or immunoregulatory (M2). We found that a switch from an M1- to an M2-dominant response occurred in microglia and peripherally derived macrophages as remyelination started. Oligodendrocyte differentiation was enhanced in vitro with M2 cell conditioned media and impaired in vivo following intra-lesional M2 cell depletion. M2 cell densities were increased in lesions of aged mice in which remyelination was enhanced by parabiotic coupling to a younger mouse and in multiple sclerosis lesions that normally show remyelination. Blocking M2 cell-derived activin-A inhibited oligodendrocyte differentiation during remyelination in cerebellar slice cultures. Thus, our results indicate that M2 cell polarization is essential for efficient remyelination and identify activin-A as a therapeutic target for CNS regeneration.

Pubmed ID: 23872599 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Associated grants

  • Agency: Howard Hughes Medical Institute, United States
  • Agency: Wellcome Trust, United Kingdom
    Id: 089000
  • Agency: Medical Research Council, United Kingdom
    Id: G0802545
  • Agency: Wellcome Trust, United Kingdom
  • Agency: Wellcome Trust, United Kingdom
    Id: 079249
  • Agency: Medical Research Council, United Kingdom
    Id: G0300336

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-Ankyrin-G (Staining) Antibody (antibody)

RRID:AB_10673030

This monoclonal targets Ankyrin-G (Staining)

View all literature mentions

Anti-Ankyrin-G (Staining) Antibody (antibody)

RRID:AB_10697718

This monoclonal targets Ankyrin-G (staining) scaffold protein

View all literature mentions